Research programme: GPBAR1 protein agonists - Exelixis

Drug Profile

Research programme: GPBAR1 protein agonists - Exelixis

Alternative Names: TGR5 protein agonists - Exelixis; XL-475

Latest Information Update: 05 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 05 Jun 2014 Discontinued - Preclinical for Metabolic disorders in USA (unspecified route)
  • 01 Aug 2013 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)
  • 13 Oct 2010 Exelixis grants Bristol-Myers Squibb an exclusive worldwide licence to its small molecule TGR5 agonist programme including back-up compounds subject to antitrust clearance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top